BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

EP: 1.Brief Overview of Chronic Lymphocytic Leukemia

EP: 2.Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

EP: 3.Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

Now Viewing

EP: 4.BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

EP: 5.Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

EP: 6.Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

EP: 7.Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

EP: 8.Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

EP: 9.Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

EP: 10.Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

EP: 11.Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

EP: 12.Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

EP: 13.Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

EP: 14.Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

EP: 15.Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

EP: 16.Unmet Needs and Future Directions in Care in CLL

Transcript:

Sonali M. Smith, MD: What we’ve talked about so far has been the frontline setting, and you’ve heard about some of the NCCN [National Comprehensive Cancer Network] indications and some of the guidelines there. I’m going to switch now to the relapsed and refractory setting, and I’m going to ask Sameer to talk to us a bit about the ASCEND trial 4-year follow-up and what that might mean for practice.

Sameer A. Parikh, MD: I think ASCEND was an important study because it was one of the first that compared 2 novel agents, if you will, in the relapsed/refractory setting for chronic lymphocytic leukemia [CLL]. To remind everyone, ASCEND was a phase 3 study that compared acalabrutinib at a dose of 100 mg twice a day to the investigator’s choice of either idelalisib and rituximab, or bendamustine and rituximab. In this study, there was a clear improvement in progression-free survival with the use of acalabrutinib. About three-quarters of all patients in the comparator arm ended up being on idelalisib as investigator’s choice, but regardless of what treatment was used in the comparator arm, acalabrutinib therapy was associated with improved progression-free survival. That showed and paved the way for approval of acalabrutinib in the relapsed setting for CLL and is available in that area for patients who need treatment after frontline chemoimmunotherapy, which is the vast majority of the patients, at least right now.

Transcript edited for clarity.